FDA whiplash for Moderna’s mFlusiva obscures a scientific asset

By Grant Colby · Reporting from Amarillo · August 6, 2026

The details are always the same when Washington decides to play God with basic medicine. First, there’s the technological breakthrough—in this case, Moderna's mFlusiva, an mRNA-based flu vaccine.

The Regulatory Whiplash Required for a Simple Shot

The details are always the same when Washington decides to play God with basic medicine. First, there’s the technological breakthrough—in this case, Moderna's mFlusiva, an mRNA-based flu vaccine. Second, there is the inevitable regulatory spectacle. I read reports detailing how the Food and Drug Administration (FDA) finally moved forward with approval for this first of its kind shot, but what really stands out isn’t the science; it’s the sheer amount of bureaucratic whiplash required to get here.

The reporting from statnews.com shows a perfect microcosm of modern federal overreach: the FDA initially resisted reviewing Moderna’s application, issuing a “refusal-to-file” notice through an official like Vinay Prasad. It was a dispute that had nothing to do with public health and everything to do with institutional power plays. The fact that this controversy required Moderna to challenge the decision before the agency finally accepted the application speaks volumes about where the real friction lies—not in the science, but in the political levers of control.

Yet, when you strip away the drama—the back-and-forth and the public spats—you are left with a genuine scientific asset. The data presented to the independent advisory committee was compelling: studies involving 40,000 people aged 50 and older found that mFlusiva reduced flu cases by about 27% compared to standard shots (apnews.com). Furthermore, proponents like Dr. Flor Munoz-Rivas noted that this technology allows for a speed of manufacture crucial for national preparedness, allowing experts "to adapt more quickly to new flu strains or pandemics" (npr.org).

The Enduring Lesson of Smallpox Development

My concern has always been the government’s tendency to treat strategic assets—be they oil fields, military readiness, or basic public health tools—as levers for social control. This mRNA vaccine is a tool that promises efficiency: it can be reformulated faster than traditional egg-based vaccines. That capability, frankly, is a matter of national security and economic stability.

But the moment this breakthrough was announced, the conversation immediately veered away from efficacy and toward mandates. The focus shifted to what could be controlled, rather than what should be protected. This pattern—the genuine scientific advance followed by the immediate threat of government overreach—is deeply familiar. It is a predictable American failure: mistaking competence for coercion.

The true measure of this development isn't found in the celebratory quotes from Moderna CEO Stéphane Bancel about "continued scientific innovation," but in history itself. We must look back to the successful eradication of smallpox by the World Health Organization between 1958 and 1977. That monumental achievement, which made smallpox the only human disease ever eradicated, did not come through a series of mandates or regulatory panic; it came from a global commitment to scientific rigor and trust in proven methods.

Strength is Built on Empirical Observation, Not Decree

The parallel between Smallpox vaccine development and today’s mFlusiva approval is undeniable: both required overcoming deep-seated public and institutional skepticism regarding novel biological agents. The shared mechanism—using an observed agent to confer immunity against a deadly threat—is the enduring constant. In 1796, Edward Jenner demonstrated that cowpox conferred immunity against smallpox. That success was built on empirical observation, not federal decree.

What separates the Smallpox campaign from today's regulatory circus is the fundamental difference in motive and application. The goal of eliminating a killer disease for the benefit of all Americans was singular and clear. Today, however, this advanced technology is being treated like another potential point of leverage—a new way to expand federal power.

The strength of this country has always rested on its ability to innovate and adapt, whether it’s building logistics firms across two decades or developing advanced vaccines. We should embrace mFlusiva for what it is: a powerful, adaptable scientific asset that strengthens our population's resilience. But we must refuse to let the spectacle of government regulation obscure the fact that this technology deserves respect as a tool—a tool whose benefit outweighs any temporary side effect and whose potential must be governed by science alone.

FDA whiplash for Moderna’s mFlusiva obscures a scientific asset

The Regulatory Whiplash Required for a Simple Shot

The Enduring Lesson of Smallpox Development

Strength is Built on Empirical Observation, Not Decree

Sources